{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:23:21Z","timestamp":1784816601298,"version":"3.55.0"},"reference-count":33,"publisher":"Nihon University School of Dentistry","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Oral Sci","Journal of Oral Science"],"published-print":{"date-parts":[[2020]]},"DOI":"10.2334\/josnusd.19-0130","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T22:36:04Z","timestamp":1580250964000},"page":"79-83","source":"Crossref","is-referenced-by-count":8,"title":["Effects of zoledronic acid and geranylgeraniol on angiogenic gene expression in primary human osteoclasts"],"prefix":"10.2334","volume":"62","author":[{"given":"Sobia","family":"Zafar","sequence":"first","affiliation":[{"name":"Discipline of Paediatric Dentistry, School of Dentistry, The University of Queensland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"P. Cullinan","sequence":"additional","affiliation":[{"name":"Discipline of Periodontics, School of Dentistry, The University of Queensland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"K. Drummond","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dentistry, Leeds Dental Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"J. Seymour","sequence":"additional","affiliation":[{"name":"Discipline of Periodontics, School of Dentistry, The University of Queensland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"E. Coates","sequence":"additional","affiliation":[{"name":"Department of Oral Sciences, Faculty of Dentistry, University of Otago"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1160","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev, doi.org\/10.1002\/14651858.CD003474.pub2,","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smith MR (2005) Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 31, 19-25.","DOI":"10.1016\/j.ctrv.2005.09.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mystakidou K, Katsouda E, Stathopoulou E, Vlahos L (2005) Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat Rev 31, 303-311.","DOI":"10.1016\/j.ctrv.2005.03.005"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Siddiqi A, Payne AG, Zafar S (2009) Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108, e1-8.","DOI":"10.1016\/j.tripleo.2009.04.027"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM et al. (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302, 1055-1061.","DOI":"10.1124\/jpet.102.035295"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ikebe T (2013) Pathophysiology of BRONJ: drug-related osteoclastic disease of the jaw. Oral Sciences Int 10, 1-8.","DOI":"10.1016\/S1348-8643(12)00045-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12, 6222s-6230s.","DOI":"10.1158\/1078-0432.CCR-06-0843"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zafar S, Coates DE, Cullinan MP, Drummond BK, Milne T, Seymour GJ (2014) Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts. J Oral Pathol Med 43, 711-721.","DOI":"10.1111\/jop.12181"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zafar S, Coates DE, Cullinan MP, Drummond BK, Milne T, Seymour GJ (2016) Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts. Clin Oral Investig 20, 2023-2035.","DOI":"10.1007\/s00784-015-1706-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. McTaggart SJ (2006) Isoprenylated proteins. Cell Mol Life Sci 63, 255-267.","DOI":"10.1007\/s00018-005-5298-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A et al. (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13, 816-823.","DOI":"10.1158\/1078-0432.CCR-06-2258"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cackowski FC, Roodman GD (2007) Perspective on the osteoclast: an angiogenic cell? Ann N Y Acad Sci 1117, 12-25.","DOI":"10.1196\/annals.1402.073"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wai PY, Kuo PC (2004) The role of osteopontin in tumor metastasis. J Surg Res 121, 228-241.","DOI":"10.1016\/j.jss.2004.03.028"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yin G, Bai Y, Luo E (2011) Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw. Med Hypotheses 76, 347-349.","DOI":"10.1016\/j.mehy.2010.10.036"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wang J, Stern PH (2011) Dose-dependent differential effects of risedronate on gene expression in osteoblasts. Biochem Pharmacol 81, 1036-1042.","DOI":"10.1016\/j.bcp.2011.01.025"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ohlrich EJ, Coates DE, Cullinan MP, Milne TJ, Zafar S, Zhao Y et al. (2016) The bisphosphonate zoledronic acid regulates key angiogenesis-related genes in primary human gingival fibroblasts. Arch Oral Biol 63, 7-14.","DOI":"10.1016\/j.archoralbio.2015.11.013"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nakagawa T, Ohta K, Kubozono K, Ishida Y, Naruse T, Takechi M et al. (2015) Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. Arch Oral Biol 60, 557-565.","DOI":"10.1016\/j.archoralbio.2014.09.012"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nagaoka Y, Kajiya H, Ozeki S, Ikebe T, Okabe K (2015) Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition. J Dent Res 94, 594-601.","DOI":"10.1177\/0022034514564187"},{"key":"19","unstructured":"19. Li P, Zhao Z, Wang L, Jin X, Shen Y, Nan C et al. (2018) Minimally effective concentration of zoledronic acid to suppress osteoclasts in vitro. Exp Ther Med 15, 5330-5336."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sainson RC, Johnston DA, Chu HC, Holderfield MT, Nakatsu MN, Crampton SP et al. (2008) TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111, 4997-5007.","DOI":"10.1182\/blood-2007-08-108597"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Qi XF, Kim DH, Yoon YS, Jin D, Huang X, Li JH et al. (2009) Essential involvement of cross-talk between IFN-gamma and TNF-alpha in CXCL10 production in human THP-1 monocytes. J Cell Physiol 220, 690-697.","DOI":"10.1002\/jcp.21815"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89, 207-215.","DOI":"10.1038\/icb.2010.158"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO et al. (2011) CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22, 121-130.","DOI":"10.1016\/j.cytogfr.2011.06.001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sahin H, Wasmuth HE (2013) Chemokines in tissue fibrosis. BBA 1832, 1041-1048.","DOI":"10.1016\/j.bbadis.2012.11.004"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR (2006) CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol 176, 4235-4243.","DOI":"10.4049\/jimmunol.176.7.4235"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lee JH, Kim HN, Kim KO, Jin WJ, Lee S, Kim HH et al. (2012) CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Cancer Res 72, 3175-3186.","DOI":"10.1158\/0008-5472.CAN-12-0481"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yazid MD, Zainal Ariffin SH, Senafi S, Zainal Ariffin Z, Megat Abdul Wahab R (2011) Stem cell heterogeneity of mononucleated cells from murine peripheral blood: molecular analysis. ScientificWorldJournal 11, 2150-2159.","DOI":"10.1100\/2011\/340278"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342, 1350-1358.","DOI":"10.1056\/NEJM200005043421807"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zhu HJ, Burgess AW (2001) Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun 4, 321-330.","DOI":"10.1006\/mcbr.2001.0301"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Govinden R, Bhoola KD (2003) Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 98, 257-265.","DOI":"10.1016\/S0163-7258(03)00035-4"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Khan UA, Hashimi SM, Bakr MM, Forwood MR, Morrison NA (2016) CCL2 and CCR2 are essential for the formation of osteoclasts and foreign body giant cells. J Cell Biochem 117, 382-389.","DOI":"10.1002\/jcb.25282"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Knowles HJ (2015) Hypoxic regulation of osteoclast differentiation and bone resorption activity. Hypoxia (Auckl) 3, 73-82.","DOI":"10.2147\/HP.S95960"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Verlinden L, Kriebitzsch C, Beullens I, Tan BK, Carmeliet G, Verstuyf A (2013) Nrp2 deficiency leads to trabecular bone loss and is accompanied by enhanced osteoclast and reduced osteoblast numbers. Bone 55, 465-475.","DOI":"10.1016\/j.bone.2013.03.023"}],"container-title":["Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/62\/1\/62_19-0130\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T03:56:59Z","timestamp":1580529419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/62\/1\/62_19-0130\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2334\/josnusd.19-0130","relation":{},"ISSN":["1343-4934","1880-4926"],"issn-type":[{"value":"1343-4934","type":"print"},{"value":"1880-4926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}